Stockscreener 앱 받기
54.59
0.87%
-0.48
전일 마감가:
$55.07
열려 있는:
$55
하루 거래량:
2.00M
Relative Volume:
0.71
시가총액:
$10.49B
수익:
$2.95B
순이익/손실:
$523.88M
주가수익비율:
20.29
EPS:
2.69
순현금흐름:
$620.18M
1주 성능:
-7.40%
1개월 성능:
+5.45%
6개월 성능:
-6.51%
1년 성능:
-10.87%
1일 변동 폭
$54.58
$55.23
1주일 범위
$54.36
$59.03
52주 변동 폭
$50.76
$73.51
바이오마린 Stock (BMRN) Company Profile
명칭
Biomarin Pharmaceutical Inc
전화
(415) 506-6700
주소
105 DIGITAL DRIVE, NOVATO, CA
BMRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
54.59 | 10.58B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
바이오마린 Stock (BMRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-03 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-09-08 | 개시 | H.C. Wainwright | Neutral |
| 2025-09-03 | 개시 | Raymond James | Outperform |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-02-24 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-30 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-20 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | 개시 | Evercore ISI | Outperform |
| 2023-11-15 | 개시 | Wells Fargo | Overweight |
| 2023-10-23 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | 개시 | Raymond James | Mkt Perform |
| 2023-09-18 | 개시 | UBS | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-07-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2023-02-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-02-21 | 개시 | Citigroup | Neutral |
| 2023-01-30 | 개시 | BMO Capital Markets | Market Perform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2022-10-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2022-04-25 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-09-09 | 업그레이드 | Stifel | Hold → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-04 | 재개 | Guggenheim | Buy |
| 2021-03-01 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-08-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2020-08-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | 재확인 | Citigroup | Buy |
| 2020-01-28 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-27 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-24 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-04-09 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-07 | 재확인 | Stifel | Buy |
| 2018-08-03 | 재확인 | Stifel | Buy |
모두보기
바이오마린 주식(BMRN)의 최신 뉴스
Aug Volume: Is BioMarin Pharmaceutical Inc stock risky to hold nowDividend Hike & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Korea’s Ildong promotes Chae Joon Lee to co-CEO - BioCentury
FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock? - Finviz
Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term - Yahoo Finance
BioMarin’s PALace Study: Long-Term Safety Check on Palynziq and What It Means for Investors - TipRanks
Zacks.com featured highlights include Universal Health Services, PNC Financial Services, Global Payments and BioMarin Pharmaceutical - The Globe and Mail
11 potential new genetic-disease medicines as BioMarin maps $4B push - Stock Titan
BioMarin drops development of liver, lung disease asset - MSN
Humana Partners With Atlas to Enhance Cancer Care for Seniors - TradingView — Track All Markets
4 Value Stocks to Buy As Wall Street Weighs Trump Policies - The Globe and Mail
BioMarin names Arpit Davé as Chief Digital and Information Officer - The American Bazaar
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - sharewise.com
BMRN or TARS: Which Is the Better Value Stock Right Now? - Yahoo Finance
Is BioMarin Pharmaceutical (BMRN) a Great Value Stock Right Now? - Yahoo Finance
BioMarin Pharmaceutical touts $3.2B 2025 revenue, Voxzogo surge and Amicus deal at JPM Conference - MarketBeat
BioMarin Pharmaceutical Reports Preliminary 2025 Revenue, Details Asset Write-Down - marketscreener.com
BioMarin appoints Arpit Davé as chief digital and information officer By Investing.com - Investing.com Nigeria
Lobbying Update: $30,000 of BIOMARIN PHARMACEUTICAL INC. lobbying was just disclosed - Quiver Quantitative
BioMarin appoints Arpit Davé as chief digital and information officer - Investing.com
Biomarin Pharmaceutical Inc estimates $3.2 billion in total revenues for FYSEC filing - marketscreener.com
BioMarin Pharmaceutical Names Arpit Dave Chief Digital and Information Officer - marketscreener.com
BMRN: Strong growth, pipeline progress, and Amicus integration position for sustained double-digit CAGR - TradingView — Track All Markets
BioMarin Appoints Arpit Davé Chief Digital and Information Officer - Yahoo Finance
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - Yahoo Finance
Why (BMRN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Veeva and BioMarin form strategic partnership to accelerate therapies By Investing.com - Investing.com Nigeria
How BioMarin Pharmaceutical Inc. (BM8) stock compares with tech leaders2025 EndofYear Setup & AI Powered Buy/Sell Recommendations - ulpravda.ru
Veeva and BioMarin Form Long-Term Strategic Partnership - Sahm
What RSI levels show for BioMarin Pharmaceutical Inc. (BM8) stockPortfolio Performance Summary & High Accuracy Investment Entry Signals - ulpravda.ru
BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA - Chartmill
Will BioMarin Pharmaceutical Inc. stock outperform Nasdaq indexIPO Watch & Stepwise Entry/Exit Trade Alerts - ulpravda.ru
What catalysts could drive BioMarin Pharmaceutical Inc. stock higher2025 EndofYear Setup & Fast Exit and Entry Trade Guides - ulpravda.ru
Is BioMarin Pharmaceutical Inc. (BM8) stock a buy during volatile marketsPortfolio Risk Report & Free Community Consensus Stock Picks - ulpravda.ru
California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare-disease company with a presence in Philadelphia - MSN
Veeva, BioMarin Enter Long-Term Strategic Partnership - Contract Pharma
Veeva Systems Expands Long-Term Partnership With BioMarin Pharmaceutical - Nasdaq
Veeva and BioMarin form strategic partnership to accelerate therapies - Investing.com
Veeva-BioMarin tech partnership to help speed new medicines to patients - Stock Titan
BioMarin fends off Kuvan generics competition again - The Pharma Letter
Robeco Institutional Asset Management B.V. Boosts Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Published on: 2026-01-08 12:48:27 - Улправда
HC Wainwright: BioMarin’s (BMRN) Amicus acquisition stabilizes cash flow while Voxzogo remains near-term driver - MSN
10 Magnificent Stocks That Can Make You Richer in 2026 - The Motley Fool
Taking a Fresh Look at BioMarin Pharmaceutical’s (BMRN) Valuation After Its Recent Share Price Rebound - Sahm
How Investors Are Reacting To BioMarin (BMRN) Halting BMN349 And Refocusing Its Rare Disease Pipeline - Yahoo Finance
19,329 Shares in BioMarin Pharmaceutical Inc. $BMRN Acquired by Financiere des Professionnels Fonds d investissement inc. - MarketBeat
Technical Analysis: What RSI levels show for BioMarin Pharmaceutical Inc BM8 stock2025 Market Trends & Free Expert Verified Stock Movement Alerts - moha.gov.vn
Investor Mood: How BioMarin Pharmaceutical Inc stock performs in weak economyJuly 2025 Pullbacks & Safe Entry Trade Reports - moha.gov.vn
Blue Trust Inc. Sells 17,973 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance - FinancialContent
These Bay Area drugmakers are hurtling toward key FDA approval decisions in 2026 - The Business Journals
바이오마린 (BMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):